# Ocular Therapeutix (OCUL) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/OCUL
## Company Profile
- Ticker: OCUL
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Ophthalmology
## Stock Data
- Close: 8.5 USD
- Market cap: 1819560574.98 USD
- Last updated: 2026-08-05
## Business Overview
### Sustained Ocular Drug Delivery
Ocular Therapeutix develops bioresorbable hydrogel implants designed to deliver drugs within the eye for extended periods. Its lead franchise seeks to reduce the frequency of anti-VEGF injections for retinal vascular diseases.
### AXPAXLI
AXPAXLI is an intravitreal hydrogel implant containing axitinib, a multi-target tyrosine kinase inhibitor with anti-angiogenic activity. The product is designed to sustain disease control in wet age-related macular degeneration and diabetic retinal disease.
### Wet AMD Registrational Program
The Phase 3 SOL-1 trial demonstrated superiority in treatment-naïve wet AMD and provides the basis for a planned NDA using Week 52 results, subject to FDA discussions. SOL-R is a separate Phase 3 non-inferiority study, while SOL-X follows patients from both pivotal trials over a longer period.
### Diabetic Retinopathy Expansion
HELIOS-3 is an ongoing Phase 3 trial of AXPAXLI in non-proliferative diabetic retinopathy. This study extends the same sustained-delivery technology into an earlier-stage retinal disease population.
## Why The Stock Is Moving

As of Aug 5, 2026, OCUL closed down 1.05% at $8.50. No new same-company headline was identified in the current news window.

## Future Catalysts

- AXPAXLI regulatory and diabetic-retinopathy program updates expected at the June 17, 2026 Investor Day.
- Planned AXPAXLI NDA submission for wet AMD based on SOL-1 Week 52 results, subject to FDA alignment.
- Topline results from the Phase 3 SOL-R wet AMD trial expected in the first quarter of 2027.

## Recent News
- 2026-08-03 11:00 EST — [Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights](https://biopharmsignal.com/news/OCUL/ocular-therapeutix-reports-second-quarter-2026-financial-results-and-business-hi-0807f056) — Source: Ocular Therapeutix
- 2026-07-09 20:05 EST — [Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/OCUL/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-b366a42e) — Source: Ocular Therapeutix
- 2026-07-01 11:00 EST — [Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences](https://biopharmsignal.com/news/OCUL/ocular-therapeutix-to-participate-in-july-scientific-and-investor-conferences-339a542b) — Source: Ocular Therapeutix
- 2026-06-17 12:45 EST — [Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026](https://biopharmsignal.com/news/OCUL/ocular-therapeutix-investor-day-to-highlight-u-s-fda-alignment-on-axpaxli-nda-wi-72a30a89) — Source: Ocular Therapeutix
- 2026-06-04 11:00 EST — [Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026](https://biopharmsignal.com/news/OCUL/ocular-therapeutix-to-participate-in-clinical-trials-at-the-summit-2026-160a01c1) — Source: Ocular Therapeutix